GB9917012D0 - Combined preparations comprising antitumor agents - Google Patents

Combined preparations comprising antitumor agents

Info

Publication number
GB9917012D0
GB9917012D0 GBGB9917012.8A GB9917012A GB9917012D0 GB 9917012 D0 GB9917012 D0 GB 9917012D0 GB 9917012 A GB9917012 A GB 9917012A GB 9917012 D0 GB9917012 D0 GB 9917012D0
Authority
GB
United Kingdom
Prior art keywords
antitumor agents
combined preparations
preparations
combined
antitumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9917012.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Priority to GBGB9917012.8A priority Critical patent/GB9917012D0/en
Publication of GB9917012D0 publication Critical patent/GB9917012D0/en
Priority to AU59839/00A priority patent/AU5983900A/en
Priority to PCT/EP2000/006540 priority patent/WO2001005425A2/en
Priority to EP00945903A priority patent/EP1200098A2/en
Priority to JP2001510479A priority patent/JP2003504413A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9917012.8A 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents Ceased GB9917012D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9917012.8A GB9917012D0 (en) 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents
AU59839/00A AU5983900A (en) 1999-07-20 2000-07-10 Combined preparations comprising antitumor agents
PCT/EP2000/006540 WO2001005425A2 (en) 1999-07-20 2000-07-10 Combined preparations comprising daunorubicin derivatives and her2 antibodies
EP00945903A EP1200098A2 (en) 1999-07-20 2000-07-10 Combined preparations comprising daunorubicin derivatives and anti her2 antibodies
JP2001510479A JP2003504413A (en) 1999-07-20 2000-07-10 Combination preparation containing an antitumor substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9917012.8A GB9917012D0 (en) 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents

Publications (1)

Publication Number Publication Date
GB9917012D0 true GB9917012D0 (en) 1999-09-22

Family

ID=10857596

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9917012.8A Ceased GB9917012D0 (en) 1999-07-20 1999-07-20 Combined preparations comprising antitumor agents

Country Status (5)

Country Link
EP (1) EP1200098A2 (en)
JP (1) JP2003504413A (en)
AU (1) AU5983900A (en)
GB (1) GB9917012D0 (en)
WO (1) WO2001005425A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE441433T1 (en) 2000-05-19 2009-09-15 Genentech Inc GENETIC DETECTION METHOD TO IMPROVE THE PROBABILITY OF AN EFFECTIVE RESPONSE TO CANCER THERAPY WITH A HERITAGE ANTAGONIST
GB0114654D0 (en) * 2001-06-15 2001-08-08 Pharmacia & Upjohn Spa Anti-tumor compound
ZA200706017B (en) 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
MX2009008981A (en) 2007-03-02 2009-09-02 Genentech Inc Predicting response to a her inhibitor.
ES2417148T3 (en) 2007-06-08 2013-08-06 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
TWI461211B (en) 2009-03-20 2014-11-21 Genentech Inc Anti-her antibodies
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2536748B1 (en) 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP2014526891A (en) 2011-08-17 2014-10-09 ジェネンテック， インコーポレイテッド Neuregulin antibodies and their use
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
RU2019103083A (en) 2011-11-30 2019-03-22 Дженентек, Инк. Mutations of ErbB3 in Cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
CA2889298C (en) 2012-11-30 2024-01-02 Anton Belousov Identification of patients in need of pd-l1 inhibitor cotherapy
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
PT110526B (en) 2018-01-26 2021-02-04 Univ Nova De Lisboa ANTIBODY, FUNCTIONAL FRAGMENT OR PROBE OF THE SAME AGAINST TUMORAL ANTIGENS
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CA2357525A1 (en) * 1999-01-27 2000-08-03 Cornell Research Foundation, Inc. Treating cancers associated with overexpression of her-2/neu
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
CA2374085C (en) * 1999-05-14 2015-12-29 Genentech, Inc. Tumour treatment with anti-erbb2 antibodies

Also Published As

Publication number Publication date
WO2001005425A2 (en) 2001-01-25
EP1200098A2 (en) 2002-05-02
WO2001005425A3 (en) 2001-05-17
AU5983900A (en) 2001-02-05
JP2003504413A (en) 2003-02-04

Similar Documents

Publication Publication Date Title
GB9917012D0 (en) Combined preparations comprising antitumor agents
HUP0101237A3 (en) Sustained release preparations
MXPA02001508A (en) Arylmethylcarbonylaminothiazole derivatives and their use as antitumor agents.
GB9905010D0 (en) Therapeutic agents
AU2002224595A1 (en) Antitumor agents
GB9909925D0 (en) Combined preparations comprising anthracycline derivatives
GB9904786D0 (en) Therapeutic agents
EP1154755A4 (en) Liposome formulations
HK1047241A1 (en) Radioprotecting agent
GB9903476D0 (en) Therapeutic agents
GB9926529D0 (en) Targeting agents
AU7446000A (en) Antitumor agents
HUP0200483A3 (en) Liposome preparations
GB9903119D0 (en) Therapeutic agents
EP1170018A4 (en) Ligand-bonded complex
EP1142589A4 (en) Medicinal preparations
GB9929801D0 (en) Anti-cancer agents iii
AU8252101A (en) Oct preparations
GB9902881D0 (en) Therapeutic agents
EP1201245A4 (en) Functional oral preparations
EP0998924A4 (en) Antitumor agents
EP1157700A4 (en) Anti-hiv agent
GB9901794D0 (en) Therapeutic preparations
SI1056704T1 (en) Antitumor agents
GB9902723D0 (en) Homogeneous aqueous preparations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)